There are 2 techniques for detecting red blood cell survival (RBCS) detection techniques: red blood cell labeling test and carbon monoxide (CO) breath test. The former has disadvantages such as long measurement times and complicated procedures, while the latter is simple, convenient, moderately priced, and capable of dynamically monitoring changes in RBCS before and after treatment. Currently, the CO breath test is gradually being implemented in clinical practice. RBCS is not only applied to hematologic diseases such as multiple myeloma, myelodysplastic syndromes, lymphoma, and thalassemia, but also to non-hematologic diseases like type 2 diabetes and chronic kidney disease. It can assist in diagnosis, guide treatment, evaluate drug treatment efficacy, and predict disease progression.
红细胞寿命(red blood cell survival，RBCS)检测技术有2种：一种是红细胞标记试验，另一种是一氧化碳(carbon monoxide，CO)呼气试验，前者存在测量时间长、操作繁琐等缺点；而后者具有简单、便捷、价格适中，以及可动态监测治疗前后RBCS变化等优点，目前已在临床上逐步开展。RBCS不仅应用于多发性骨髓瘤、骨髓增生异常综合征、淋巴瘤、地中海贫血等血液系统病，还可应用于2型糖尿病和慢性肾脏病等非血液系统疾病；可辅助诊断、指导治疗、评估药物治疗效果、预测疾病的进展。.
Keywords: anemia; carbon monoxide breath test; clinical application; red blood cell survival.